Mean clinical recovery time reduced from 26 days (SOC) to 9 days,
p<0.0001 (HCQ+AZ) or 13 days,
p<0.0001 (AZ). No cardiac toxicity. Small retrospective study of 88 patients with case control analysis with matched patients.
Guérin et al., 5/31/2020, retrospective, France, Europe, peer-reviewed, 8 authors, dosage 600mg days 1-10, 7-10 days.
risk of death, 61.4% lower, RR 0.39, p = 1.00, treatment 0 of 20 (0.0%), control 1 of 34 (2.9%).
recovery time, 65.0% lower, relative time 0.35, p < 0.001.